FOUNDATIONONE®CDx

As our understanding of cancer evolves, so do our tests: FoundationOne®CDx gene list

Up-to-date gene lists powered by the latest genomic insights

Our genomic database is one of the largest in the world and continuously growing, and currently contains >180,000 genomic profiles in >150 tumour subtypes*[1]

Our gene panels are regularly refined to capture the most clinically relevant genomic alterations so you can consider the latest treatment options[1]

The FoundationOne CDx gene list is updated from the FoundationOne gene list, with 59 genes added and 56 genes removed[2,3]

59 added genes provide more insights to help personalise your patients' treatment plans[2]

Therapy	Clinical trials	Prognosis	Diagnosis or germline	Potential or unknown clinical significance
RAD51C†	*RAD51B*‡, *RAD51C*§, *RAD51D*§	*BTG2, CASP8, CUL4A, CYP17A1, DDR1, EPHB4, MAF, MSH3, MST1R, MTAP, PARP1, PIM1, PPP2R2A, PTPRO, RAD21, SDC4, SGK1, SLC34A2, TYRO3*	*CXCR4, CYP17A1, EED, ERCC4, MSH3, PARP1, PPARG, RAD51C, RAD51D, NBN, RAD21*	*ALOX12B, CALR, CD22, CD70, CD74, CSF3R, DIS3, EZR, FGF12, HDAC1, ID3, LTK, MAP3K13, MAPK1, MERTK, MKNK1, NT5C2, NUTM1, P2RY8, PARP2, PARP3, PDCD1, PIK3C2G, RAD52, RAD54L, REL, RSPO2, TEK, TIPARP, WHSC1, WHSC1L1, XRCC2*

* As of August 2018.
† RAD51C: Therapies shown for specific inactivating alterations in solid tumours: olaparib, rucaparib, and niraparib.
‡ RAD51B: Clinical trials for PARP inhibitors shown for specific inactivating alterations in ovarian cancers.
§ RAD51C and RAD51D: Clinical trials for PARP inhibitors shown for specific inactivating alterations in solid tumours.

FOUNDATION MEDICINE® | Roche

FOUNDATIONONE®CDx

FoundationOne CDx full gene list[2,3]

List reads from left to right: A-Z.
Green indicates new genes.*

Genes with full coding exonic regions: For detection of substitutions, insertion-deletions and copy-number alterations

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	**ALOX12B**	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	**BTG2**
BTK	C11orf30 (EMSY)	**CALR**	CARD11	**CASP8**	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	**CD22**	CD274 (PD-L1)	**CD70**	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	**CSF3R**	CTCF
CTNNA1	CTNNB1	CUL3	**CUL4A**	**CXCR4**	**CYP17A1**	DAXX	**DDR1**	DDR2
DIS3	DNMT3A	DOT1L	**EED**	EGFR	EP300	EPHA3	EPHB1	**EPHB4**
ERBB2	ERBB3	ERBB4	**ERCC4**	ERG	ERRFI1	ESR1	EZH2	FAM46C
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	**FGF12**	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	**ID3**	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	**LTK**	LYN	**MAF**	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	**MAP3K13**	**MAPK1**	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	**MKNK1**	MLH1	MPL	MRE11A	MSH2	**MSH3**
MSH6	**MST1R**	**MTAP**	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	**NT5C2**	NTRK1	NTRK2	NTRK3	**P2RY8**	PALB2	PARK2
PARP1	**PARP2**	**PARP3**	PAX5	PBRM1	**PDCD1 (PD-1)**	PDCD1LG2 (PD-L2)	PDGFRA	PDGFRB
PDK1	PIK3C2B	**PIK3C2G**	PIK3CA	PIK3CB	PIK3R1	**PIM1**	PMS2	POLD1
POLE	**PPARG**	PPP2R1A	**PPP2R2A**	PRDM1	PRKAR1A	PRKCI	PTCH1	PTEN
PTPN11	**PTPRO**	QKI	RAC1	**RAD21**	RAD51	**RAD51B**	**RAD51C**	**RAD51D**
RAD52	**RAD54L**	RAF1	RARA	RB1	RBM10	**REL**	RET	RICTOR
RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2	SF3B1
SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOCS1	SOX2
SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU	SYK
TBX3	**TEK**	TET2	TGFBR2	**TIPARP**	TNFAIP3	TNFRSF14	TP53	TSC1
TSC2	**TYRO3**	U2AF1	VEGFA	VHL	**WHSC1 (MMSET)**	**WHSC1L1**	WT1	XPO1
XRCC2	ZNF217	ZNF703						

*Compared to the FoundationOne gene list.

Select rearrangements: Genes from select intronic regions for the detection of gene rearrangements

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	**CD74**	EGFR	ETV4
ETV5	ETV6	EWSR1	**EZR**	FGFR1	FGFR2	FGFR3	KIT	KM2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	**NUTM1**	PDGFRA	RAF1
RARA	RET	ROS1	**RSPO2**	**SDC4**	**SLC34A2**	TERC*	TERT (promoter only)†	
TMPRSS2								

*TERC is a non-coding RNA gene. †TERT is a gene with a promoter region.

Removed genes*

ABL2	ARID1B	ARID2	BLM	CHD2	CHD4	CRLF2	CYLD	DICER1
EPHA5	EPHA7	ETV1	FANCD2	FANCE	FANCF	FAT1	FLT4	FOXP1
FRS2	GATA1	GATA2	GLI1	GPR124	GRIN2A	HSP90AA1	IL7R	INHBA
KMT2C	LMO1	LRP1B	LZTR1	MAGI2	MYST3	NSD1	NUP93	PAK3
PIK3CG	PLCG2	PREX2	PRKDC	PRSS8	RAD50	RANBP2	RUNX1	RUNX1T1
SLIT2	SMAD3	SOX10	SPTA1	STAT4	TAF1	TOP1	TOP2A	TSHR
WiSP3	ZBTB2							

*56 genes previously on the FoundationOne gene list.

FOR MORE INFORMATION PLEASE CONTACT YOUR ROCHE REPRESENTATIVE

1. Foundation Medicine. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed August 2018); 2. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech; 3. FoundationOne® Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1tech.

FOUNDATION MEDICINE® | Roche

Roche Products (India) Pvt. Ltd. 1503, 15th Floor, The Capital, Plot No. C-70, Behind ICICI Bank, Bandra Kurla Complex, Bandra (E) Mumbai 400 051
The following promotional material is not valid after 30/10/2020 or any update. For the use of Registered Medical Practitioner or a Hospital or a Laboratory only. PM-IN-0192